Ovarian Cancer

Study declares new markers of ovarian cancer be judged against CA125

Published in Proteomics Weekly, November 7th, 2005

A recent study declares that new markers of ovarian cancer shoulg be judged against CA125.

Researchers in Ireland reported, "CA125 is currently the most widely used tumor marker for ovarian epithelial cancer. The aim of the article by "M. J. Duffy and colleagues, St. Vincents Hospital, "was to provide guidelines for the routine clinical use of CA125 in patients with ovarian cancer."

"Due to lack of sensitivity for stage I disease and lack of specificity, CA125 is of little value in the detection of early ovarian cancer," explained the scientists. "At present, therefore, CA125, either alone or in combination with other modalities, cannot be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2005-11-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry